Skip to main content
Have a personal or library account? Click to login
Complications in Patients with STEMI versus Non-STEMI: A Clinical Comparison Cover

Complications in Patients with STEMI versus Non-STEMI: A Clinical Comparison

Open Access
|Jun 2026

Figures & Tables

FIGURE 1.

Advanced coronary artery disease, evidenced by a history of ACS, demonstrated a statistically significant higher prevalence in the NSTEMI group.

FIGURE 2.

Distribution of treated culprit lesions in patients with STEMI and NSTEMI. Left main artery involvement was significantly higher in NSTEMI patients (47.4% vs. 2.04%; p < 0.0001), whereas RCA lesions were more frequently treated in STEMI (40.81% vs. 7.4%; p < 0.0001). No statistically significant differences were observed for LAD or CX involvement.

FIGURE 3.

Distribution of hemodynamic instability in patients with STEMI compared to those with NSTEMI. The chart illustrates a significantly higher occurrence of hemodynamic instability in patients with NSTEMI (10.93%) compared to those with STEMI (0.18%), with statistical significance noted (p = 0.005).

FIGURE 4.

Comparison of ventricular arrhythmias between the two groups. The analysis showed no statistically significant difference in the incidence of hemodynamic instability between patients with NSTEMI and STEMI.

The incidence of hemodynamic instability and ventricular arrhythmias, the frequency of PTCA, the distribution of culprit lesions across major coronary arteries with PTCA, and a subanalysis for culprit treated lesions and hemodynamic instability/ventricular arrythmias

VariableSTEMI (n = 108)NSTEMI (n = 64)p value
Treated culprit lesions
PTCA9854
Left Main2 (2.04%)4 (47.4%)<0.0001
LAD57 (58.16%)29 (53.7%)ns
RCA40 (40.81%)4 (7.4%)<0.0001
CX14 (14.28%)9 (16.66%)ns
Hemodynamic instability20 (0.18%)7 (10.93%)0.005
Ventricular arrhythmias13 (12.03%)5 (7.81%)ns
Hemodynamic instability4,049 ± 6,9902,707 ± 4,380ns
PTCA - LM1 (5%)0
PTCA - LAD8 (40%)4 (57.14%)ns
PTCA - RCA8 (40%)2 (28.15%)ns
PTCA – CX3 (15%)2 (18.15%)ns
Ventricular arrhythmias
PTCA – LAD6 (46.15%)3 (60%)ns
PTCA - RCA4 (30.7%)0
PTCA – CX2 (15.38%)2 (40%)0.0001

Baseline characteristics

VariableSTEMI (n = 108)NSTEMI (n = 64)p value
Mean age61.564.030.19
Male80 (74%)48 (75%)>0.99
Previous ACS6 (4.63%)11 (17.19%)0.011
History of atrial fibrillation21 (19.44%)6 (9.38%)ns
Diabetes mellitus26 (24.07%)16 (25.00%)ns
Smoker44 (40.74%)18 (28.13%)ns
Hypertension80 (74.07%)56 (87.5%)ns
Peak hs-cTnI (ng/ml)10,422 ± 15,6365,720 ± 8,272ns
NTproBNP (pg/ml)4,049 ± 6,9902,707 ± 4,380ns
LVEF (%)40.74%43.450.05
DOI: https://doi.org/10.2478/jce-2025-0014 | Journal eISSN: 2457-5518 | Journal ISSN: 2457-550X
Language: English
Page range: 61 - 67
Submitted on: Feb 4, 2025
Accepted on: Jul 20, 2025
Published on: Jun 24, 2026
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2026 Dan Pasaroiu, Imre Benedek, Adriana Blendea, Teodora Popa, Constantin Tolescu, Monica Chitu, Theodora Benedek, published by Asociatia Transilvana de Terapie Transvasculara si Transplant KARDIOMED
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.